Monthly Archives

May 2016

Risk-Based Monitoring Insights from the Industry: Dr. Peter Schiemann

By | Blog, Insights from the Industry Blog Series | No Comments

Part Four

In the fourth installment of the CluePoints Risk-Based Monitoring Q&A series, we spoke to Dr. Peter Schiemann, Managing Partner and Co-Founder of Widler & Schiemann, who had some interesting views to share with us

When it comes to the practical implementation of Risk-Based Monitoring, where do you observe differences in current best Risk-Based Monitoring practices between companies and CROs of different size?

How will Risk-Based Monitoring Coexist with other Clinical Trial Technology?

By | Blog | No Comments

We’ve been really enjoying hearing your thoughts on the latest Risk-Based Monitoring hot topics over the last few weeks, so thank you to everyone who has taken time out to be involved. Next on our agenda is technology. As Risk-Based Monitoring takes off and becomes more mainstream within clinical studies, how will new technology exist alongside the multitude of electronic systems already in use?…

Risk-Based Monitoring Insights from the Industry: Karen Fanouillere

By | Blog, Insights from the Industry Blog Series | No Comments

Part Three

In the third of an eight-part Q&A series which aims to explore some of the current hot topics in Risk-Based Monitoring (RBM), CluePoints has been speaking with Karen Fanouillere, Biostatistics Project Leader for 15 years and now Head of Clinical Information Governance at Sanofi about the perspectives of a large pharma company in implementing new monitoring methodologies for drug development programs.